Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study
DOI:
https://doi.org/10.2340/1651-226X.2025.44327Abstract
Background and purpose: Pembrolizumab is frequently used for recurrent or metastatic head and neck squamous cell carcinoma (rmHNSCC) as first-line treatment. This study evaluates real-world effectiveness in a Danish and United Kingdom (UK) cohort.
Patient/material and methods: Patients with confirmed rmHNSCC treated with pembrolizumab (2020–2024) as first-line palliative treatment were included consecutively. Data were collected from patient files at four Danish head and neck cancer centres (discovery cohort) and the Leeds Teaching Hospitals NHS Trust (comparison cohort). Primary endpoints were overall survival (OS) and progression-free survival (PFS).
Results: In the discovery cohort (n = 228), a median OS of 10 months (95% [confidence interval [CI]: 10–12) and median PFS of 4 months (95% CI: 4–6) were found. Primary endpoints did not differ significantly between the discovery and comparison cohort. Baseline World Health Organization performance status appeared to negatively impact endpoints (hazard ratio: 1.4 [95% CI: 1.0–2.0]).
Interpretation: In this real-world multi-centre study, pembrolizumab demonstrated efficacy equivalent to the registration studies in two independent cohorts.
Downloads
References
Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.
https://doi.org/10.1056/NEJMoa1602252 DOI: https://doi.org/10.1056/NEJMoa1602252
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.
https://doi.org/10.1016/S0140-6736(18)31999-8 DOI: https://doi.org/10.1016/S0140-6736(18)31999-8
Vasiliadou I, Grose D, Wilson C, Thapa A, Donnelly O, Lee E, et al. The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK. Int J Cancer. 2024;155(5):883–93.
https://doi.org/10.1002/ijc.34963 DOI: https://doi.org/10.1002/ijc.34963
Søby S, Gothelf A, Gyldenkerne N, Bentzen J, Nowicka-Matus K, Tramm T, et al. Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study. Acta Oncol. 2022;61(8):972–8.
https://doi.org/10.1080/0284186X.2022.2103387 DOI: https://doi.org/10.1080/0284186X.2022.2103387
Kenilworth NJ. FDA approves Merck’s Keytruda (pembrolizumab) for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications [Internet]. [cited 2025 Jan 21]. Available from: https://www.drugs.com/newdrugs/fda-approves-merck-s-keytruda-pembrolizumab-additional-recommended-400-mg-every-six-weeks-all-5218.html
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.
https://doi.org/10.1016/S1470-2045(17)30074-8 DOI: https://doi.org/10.1016/S1470-2045(17)30074-8
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28.
https://doi.org/10.1016/S0140-6736(19)32591-7 DOI: https://doi.org/10.1016/S0140-6736(19)32591-7
Schougaard LM, Larsen LP, Jessen A, Sidenius P, Dorflinger L, de Thurah A, et al. AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases. Qual Life Res. 2016;25(3):525–34.
https://doi.org/10.1007/s11136-015-1207-0 DOI: https://doi.org/10.1007/s11136-015-1207-0
Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol. 2017;3(11):1511–19.
https://doi.org/10.1001/jamaoncol.2017.1588 DOI: https://doi.org/10.1001/jamaoncol.2017.1588
Tachinami H, Tomihara K, Yamada SI, Ikeda A, Imaue S, Hirai H, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab. Br J Oral Maxillofac Surg. 2023;61(4):320–6.
https://doi.org/10.1016/j.bjoms.2023.03.012 DOI: https://doi.org/10.1016/j.bjoms.2023.03.012
Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1146.
https://doi.org/10.3389/fonc.2019.01146 DOI: https://doi.org/10.3389/fonc.2019.01146
Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.
https://doi.org/10.1186/s40425-019-0768-9 DOI: https://doi.org/10.1186/s40425-019-0768-9
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Sebastian Søby, Robin Prestwich, Niels Gyldenkerne, Christian Maare, Camilla K Lonkvist, Maria Andersen, Kinga Nowicka-Matus, Anita Gothelf, Trine Tramm, Kasper Toustrup, Simion Mihaela, Danny Ulahannan, Zsuzsanna Iyizoba-Ebozue, Jesper G Eriksen
This work is licensed under a Creative Commons Attribution 4.0 International License.
